Epidemiology of urothelial carcinoma

International Journal of Urology

Volumn 24, Issue 10, 2017, Pages 730-734

  Miyazaki, Jun ^a   Nishiyama, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

epidemiology; upper tract urothelial carcinoma; urinary bladder cancer; urothelial carcinoma

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANALGESIC AGENT; CARCINOGEN; CIGARETTE SMOKE;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; ENVIRONMENTAL FACTOR; HEREDITY; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; CIGARETTE SMOKING; DISEASE EXACERBATION; ENVIRONMENT; GENETICS; HUMAN; PATHOLOGY; RISK FACTOR; URINARY TRACT TUMOR; UROTHELIUM;

CIGARETTE SMOKING; DISEASE PROGRESSION; ENVIRONMENT; HUMANS; OCCUPATIONAL EXPOSURE; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 85030221545     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13376     Document Type: Review

References (55)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016; 66: 7–30.
2. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011; 107: 1059–64.
3. Holmang S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer 2004; 101: 741–7.
4. Holmang S, Lele SM, Johansson SL. Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J. Urol. 2007; 178: 51–6.
5. Paonessa J, Beck H, Cook S. Squamous cell carcinoma of the renal pelvis associated with kidney stones: a case report. Med. Oncol. 2011; 28(Suppl 1): S392–4.
6. Minds clinical guideline 2014. [Cited 1 Apr 2014.] Available from URL: http://minds.jcqhc.or.jp/n/med/4/med0193/G0000689/0001, http://www.mhlw.go.jp/toukei/index.html.
7. Green DA, Rink M, Xylinas E et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J. Urol. 2013; 189: 1214–21.
8. Stefanovic V, Polenakovic M, Toncheva D. Urothelial carcinoma associated with Balkan endemic nephropathy. A Worldwide disease. Pathol. Biol. 2011; 59: 286–91.
9. Patel N, Arya M, Muneer A et al. Molecular aspects of upper tract urothelial carcinoma. Urol Oncol. 2014; 32: e11–20.
10. Grollman AP, Shibutani S, Moriya M et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl Acad. Sci. USA 2007; 104: 12129–34.
11. Dragicevic D, Djokic M, Pekmezovic T et al. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in Balkan endemic nephropathy and non-endemic areas of Serbia. BJU Int. 2007; 99: 1357–62.
12. Nortier JL, Martinez MC, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000; 342: 1686–92.
13. Gokmen MR, Cosyns JP, Arlt VM et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann. Intern. Med. 2013; 158: 469–77.
14. Chen CH, Dickman KG, Moriya M et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl Acad. Sci. USA 2012; 109: 8241–6.
15. Tan LB, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. BJU Int. 2008; 102: 48–54.
16. Yang MH, Chen KK, Yen CC et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002; 59: 681–7.
17. Lamm SH, Engel A, Penn CA, Chen R, Feinleib M. Arsenic cancer risk confounder in southwest Taiwan data set. Environ. Health Perspect. 2006; 114: 1077–82.
18. Colin P, Koenig P, Ouzzane A et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009; 104: 1436–40.
19. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol. Dial. Transplant. 1999; 14: 2892–7.
20. McLaughlin JK, Silverman DT, Hsing AW et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res. 1992; 52: 254–7.
21. Ehdaie B, Furberg H, Zabor EC et al. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. BJU Int. 2013; 111: 589–95.
22. Hagiwara M, Kikuchi E, Tanaka N et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J. Urol. 2013; 189: 2062–8.
23. Rink M, Xylinas E, Trinh QD et al. Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU Int. 2013; 112: 623–37.
24. Miyazaki J, Nishiyama H, Fujimoto H et al. Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: subanalysis of the Japanese Urological Association multi-institutional national database. Int. J. Urol. 2015; 22: 1023–7.
25. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer 1999; 86: 1576–82.
26. Gylling AH, Nieminen TT, Abdel-Rahman WM et al. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29: 1351–9.
27. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009; 10: 400–8.
28. Roupret M, Babjuk M, Comperat E et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur. Urol. 2015; 68: 868–79.
29. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009; 115: 68–74.
30. Hori M, Matsuda T, Shibata A et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 2015; 45: 884–91.
31. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev. 1999; 12: 97–111.
32. el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin. Oncol. 2001; 28: 174–8.
33. Salem S, Mitchell RE, El-Alim El-Dorey A, Smith JA, Barocas DA. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. BJU Int. 2011; 107: 206–11.
34. Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004; 93: 216–20.
35. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737–45.
36. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur. Urol. 2016; 70: 458–66.
37. Borzym-Kluczyk M, Radziejewska I, Zaniewska A et al. Effect of smoking on activity of N-acetyl-beta-hexosaminidase in serum and urine of renal cancer patients. Clin. Biochem. 2009; 42: 1565–7.
38. Rouissi K, Ouerhani S, Hamrita B et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol. Oncol. Res. 2011; 17: 879–86.
39. Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology 2015; 86: 968–72.
40. Chen CH, Shun CT, Huang KH et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int. 2007; 100: 281–6.
41. Hinotsu S, Akaza H, Miki T et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int. J. Urol. 2009; 16: 64–9.
42. Wilcox AN, Silverman DT, Friesen MC et al. Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project. Cancer Causes Control 2016; 27: 1429–35.
43. Fortuny J, Kogevinas M, Zens MS et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 2007; 7: 13.
44. Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int. J. Cancer 2007; 120: 2221–5.
45. Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2014; 78: 258–73.
46. Levin D, Bell S, Sund R et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58: 493–504.
47. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand. J. Urol. Nephrol. Suppl. 2008; 218: 64–78.
48. Naito S, Tanaka K, Koga H, Kotoh S, Hirohata T, Kumazawa J. Cancer occurrence among dyestuff workers exposed to aromatic amines. A Long Term Follow-up Study. Cancer 1995; 76: 1445–52.
49. Rota M, Bosetti C, Boccia S, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Arch. Toxicol. 2014; 88: 1479–90.
50. Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J. Urol. 2001; 166: 2129–33.
51. Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. Cancer 2006; 107: 705–11.
52. Murta-Nascimento C, Silverman DT, Kogevinas M et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol. Biomarkers Prev. 2007; 16: 1595–600.
53. Shinka T, Miyai M, Sawada Y, Inagaki T, Okawa T. Factors affecting the occurrence of urothelial tumors in dye workers exposed to aromatic amines. Int. J. Urol. 1995; 2: 243–8.
54. Markovic N, Ignjatovic I, Cukuranovic R, Petrovic B, Kocic B, Stefanovic V. Decreasing incidence of urothelial cancer in a Balkan endemic nephropathy region in Serbia. A surgery based study from 1969 to 1998. Pathol. Biol. 2005; 53: 26–9.
55. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008; 74: 158–69.